Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€135.60

€135.60

0.070%
0.1
0.070%
€140.00
 
13:30 / Tradegate WKN: A2AR94 / Name: Shop Apotheke Europe / Stock / Software & IT Services / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Shop Apotheke Europe NV Stock

There is nearly no change for the Shop Apotheke Europe NV stock today. Compared to yesterday it only changed by €0.10.
Currently there is a rather positive sentiment for Shop Apotheke Europe NV with 5 Buy predictions and 2 Sell predictions.
With a target price of 140 € there is a slightly positive potential of 3.24% for Shop Apotheke Europe NV compared to the current price of 135.6 €.
So far the community has only identified positive things for Shop Apotheke Europe NV stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Shop Apotheke Europe is a German-based online pharmacy that operates in the European market, offering a broad range of pharmaceutical products, health and wellness items, and beauty and personal care products. It provides customers with an easy-to-use platform to purchase goods, as well as convenient delivery options. Shop Apotheke Europe has continuously expanded its operations, including through several acquisitions, and has established itself as a leading player in the rapidly-growing market of online pharmacies. The company is listed on the Frankfurt Stock Exchange and has a market capitalization of over €1 billion.

Pros and Cons of Shop Apotheke Europe NV in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
G***** c******* t* c**********
Cons
?
B****
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Shop Apotheke Europe NV vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Shop Apotheke Europe NV 0.070% 0.669% 15.123% 22.403% 3.159% -2.166% 288.252%
Delivery Hero SE -1.660% 7.992% 38.078% 38.177% 54.040% -62.936% -4.394%
Etsy Inc -1.080% -6.045% 0.344% -18.769% -34.949% -73.464% -6.447%
Scout24 AG 0.390% -0.452% 6.634% 17.178% 20.284% 33.431% 44.476%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-06-20

Shop Apotheke Europe, a company operating in the Software & IT Services industry, appears to have mixed financial performance based on the provided data. The company has seen growth in particular areas, while also facing some challenges in its financial position. Upon analyzing the financial statements, including balance sheets, cash flows, and income statements, the following detailed analysis points out the pros and cons of the company's financials.

Growing revenue: The company's total revenue has shown consistent growth over the past few years. In 2020, the firm registered a total revenue of €968,062,000, which increased to €1,060,321,000 in 2021 and further grew to €1,204,352,000 in 2022. This indicates a strong demand for the company's products and services and can potentially lead to a healthy bottom line.

Increasing gross profit: Shop Apotheke Europe's gross profit has also increased over the years. In 2020, it was €219,528,000, which rose to €266,528,000 in 2021 and €331,786,000 in 2022. A growing gross profit demonstrates the company's ability to generate revenue efficiently and improve its overall profitability.

Comments

Buy Shop Apotheke Europe NV
Show more

Buy Shop Apotheke Europe NV
Show more

Buy Shop Apotheke Europe NV
Show more

News

EQS-News: Redcare Pharmacy achieves 81% growth in Q3 Rx sales in Germany, 108% in September and decides to accelerate marketing based on very convincing e-Rx metrics.: https://upload.wikimedia.org/wikipedia/commons/thumb/0/07/Shop_Apotheke_Europe_logo.svg/640px-Shop_Apotheke_Europe_logo.svg.png
EQS-News: Redcare Pharmacy achieves 81% growth in Q3 Rx sales in Germany, 108% in September and decides to accelerate marketing based on very convincing e-Rx metrics.
EQS-News: Redcare Pharmacy achieves 81% growth in Q3 Rx sales in Germany, 108% in September and decides to accelerate marketing based on very convincing e-Rx metrics.
EQS-Adhoc: Redcare Pharmacy achieves 81% growth in Q3 Rx sales in Germany, 108% in September and decides to accelerate marketing in Q4 based on very convincing e-Rx metrics. Full-year guidance updated.: https://upload.wikimedia.org/wikipedia/commons/thumb/0/07/Shop_Apotheke_Europe_logo.svg/640px-Shop_Apotheke_Europe_logo.svg.png
EQS-Adhoc: Redcare Pharmacy achieves 81% growth in Q3 Rx sales in Germany, 108% in September and decides to accelerate marketing in Q4 based on very convincing e-Rx metrics. Full-year guidance updated.
EQS-Adhoc: Redcare Pharmacy achieves 81% growth in Q3 Rx sales in Germany, 108% in September and decides to accelerate marketing in Q4 based on very convincing e-Rx metrics. Full-year guidance updated.
EQS-News: Redcare Pharmacy achieves rapid increase of Rx sales in Germany, continues its strong double-digit overall growth rate and closes Q2 with a solid 2.7% margin. : https://upload.wikimedia.org/wikipedia/commons/thumb/0/07/Shop_Apotheke_Europe_logo.svg/640px-Shop_Apotheke_Europe_logo.svg.png
EQS-News: Redcare Pharmacy achieves rapid increase of Rx sales in Germany, continues its strong double-digit overall growth rate and closes Q2 with a solid 2.7% margin. 
EQS-News: Redcare Pharmacy achieves rapid increase of Rx sales in Germany, continues its strong double-digit overall growth rate and closes Q2 with a solid 2.7% margin.